Intravascular Microaxial LVAD Devices Market Report 2026

The intravascular microaxial LVAD devices market size has grown rapidly in recent years. It will grow from $0.45 billion in 2025 to $0.53 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to rising prevalence of advanced heart failure cases, limited donor heart availability for transplantation, increasing adoption of temporary mechanical circulatory support, growing use of percutaneous coronary intervention procedures, expansion of cardiac catheterization laboratory infrastructure.

The intravascular microaxial LVAD devices market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion by 2030 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to increasing demand for minimally invasive cardiac support solutions, rising geriatric population with cardiovascular disorders, advancement in short term ventricular assist technologies, growing clinical preference for bridge to recovery therapies, expansion of specialized cardiac care centers globally. Major trends in the forecast period include minimally invasive percutaneous ventricular support adoption, hemocompatible blood pump material innovation, ultra-compact axial flow pump miniaturization, extended duration mechanical circulatory support optimization, catheter based cardiac intervention workflow integration.

The increasing prevalence of cardiovascular diseases is anticipated to propel the growth of the intravascular microaxial LVAD devices market in coming years. Cardiovascular diseases refer to disorders of the heart and blood vessels, including coronary artery disease, heart failure, stroke, and hypertension, that impair cardiovascular function and require ongoing clinical management. The rise in cardiovascular diseases is driven mainly by aging populations and increasing prevalence of risk factors in developed economies. Intravascular microaxial LVAD devices supports this trend by providing advanced circulatory support solutions that stabilize hemodynamics and bridge patients to recovery, transplant, or chronic support in cases of severe heart failure. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024 up 4% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the intravascular microaxial LVAD devices market.

Leading companies operating in the intravascular microaxial LVAD devices market are focusing on advancing precision cardiac support technologies, such as the ninth-generation Impella CP intravascular microaxial flow pump, to enhance hemodynamic support, improve patient survival outcomes, enable minimally invasive high-risk cardiac interventions, and optimize real-time cardiac performance monitoring. The ninth-generation Impella CP intravascular microaxial flow pump refers to an advanced catheter-based mechanical circulatory support device designed to provide enhanced left ventricular unloading and improved hemodynamic support through a miniaturized, high-efficiency axial flow pump inserted percutaneously into the heart. For example, in October 2025, Johnson & Johnson MedTech, a US-based medical technology company, highlighted the newest Impella CP and long-term survival data at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference. The newest Impella CP features optimized pump functionality for enhanced hemodynamic support, design updates that improve ease of use for clinicians, and upgraded evidence showing improved long-term survival outcomes. These innovations align with updated clinical guidelines recommending Impella for cardiogenic shock and high-risk percutaneous procedures, expanding its applicability. While cost and training requirements remain considerations, these device advancements strengthen acute cardiac support capabilities.

The rising healthcare expenditure is anticipated to propel the growth of the intravascular microaxial LVAD devices market in coming years. Healthcare expenditure refers to the total amount of financial resources spent on health services, including hospital care, medical devices, physician services, and preventive care, to improve health outcomes. The increase in healthcare expenditure is driven by factors such as the growing prevalence of cardiovascular diseases and advancements in medical technologies that require higher investment. Intravascular microaxial LVAD devices are used to provide temporary mechanical circulatory support in patients with severe cardiac conditions, improving cardiac output and stabilizing hemodynamics during high-risk procedures or acute heart failure. Increased healthcare spending enables greater access to advanced cardiac care technologies, supports hospital adoption of innovative devices, and enhances patient affordability for life-saving treatments. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure experienced a significant rise of 5.6% in nominal terms from 2022 to 2023, marking a notable acceleration from the 0.9% growth recorded in 2022. Therefore, the rising healthcare expenditure is driving the growth of the intravascular microaxial LVAD devices market.

Major companies operating in the intravascular microaxial lvad devices market are Johnson & Johnson, Abbott Laboratories, Medtronic Plc, Supira Medical Inc., Magenta Medical Ltd., Jarvik Heart Inc., Windmill Cardiovascular Systems Inc., PulseCath B. V.

North America was the dominating region in the intravascular microaxial LVAD devices market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the intravascular microaxial LVAD devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the intravascular microaxial LVAD devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravascular microaxial LVAD devices market consists of sales of catheter-based microaxial blood pumps, percutaneous ventricular assist devices, pump controllers and consoles, and related monitoring and support components. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.